GlobeNewswire

VistaJet Presents Exceptional Travel Experiences for The Collection of Peggy and David Rockefeller

Dela

Three highly personalized programs for art lovers to enhance the most significant philanthropic auction ever presented

 

LONDON, Feb. 08, 2018 (GLOBE NEWSWIRE) -- VistaJet, the first and only global private aviation company, showcases today three exclusive experiences to enrich the exhibitions and global tour of The Collection of Peggy and David Rockefeller, the most valuable auction of a private collection entirely dedicated to raising funds for philanthropic causes. 

Following the unveiling of early highlights in Hong Kong last November, the global public tour will move to London (February 21 - March 8), Paris (March 16 - 21), Beijing (April 6 - 7), Los Angeles (April 6 - 12) and Shanghai (April 10 - 11), ahead of the final exhibition in New York at Christie's Rockefeller Center from April 28 until the sale on May 7 - 11. With each stop on the pre-sale tour, additional works of art and objects will be revealed.

With 80% of customers regularly investing in art, VistaJet flies some of the world's most prominent collectors. Art has always integrated organically into the brand and as the company continuously strives to provide exceptional and curated experiences for members, anytime and anywhere, VistaJet's three fully customizable The Art of Flying Experiences* will offer exclusive previews, private dinners, lectures and talks, enriching their engagement with the Rockefeller pieces.

The World of Art Experience  will offer customers the opportunity to travel to all of The Collection of Peggy and David Rockefeller exhibitions on-board VistaJet for a private tour of the emblematic collection at each location. By booking this multi-leg journey, VistaJet will transport clients and their art at no additional cost on flights anytime, anywhere** and the experience will also include a year-long membership*** to The Cultivist, the global arts club.

The Direct Experience  will offer any guest flying with VistaJet to any of The Collection of Peggy and David Rockefeller exhibitions in London, Paris, Beijing, Shanghai, Los Angeles or New York, an invitation to receive a complimentary membership to VistaJet Direct worth $10,000. The Direct membership gives clients access to available VistaJet private flights at special rates from any mobile device, through the world's first end-to-end business jet app.

The third exclusive opportunity,  The Rockefeller  Experience , will allow up to 10 guests traveling with VistaJet on one of its iconic silver and red jets to New York, a rare opportunity for a behind the scenes private discovery tour of Kykuit, the historical National Trust landmark of the Rockefeller Estate in Pocantico Hills, before enjoying a Rockefeller-inspired multi-taste feast at an exclusive Upstate New York venue. Guests will then be invited for a personal tour of The Collection of Peggy and David Rockefeller exhibition in New York, and to view the live auction at Christie's New York with leading art experts.

"The Collection of Peggy and David Rockefeller is a unique collection of the finest works of art and objects," said Nina Flohr of VistaJet. "The fact that 100% of the proceeds from the auction of the collection will be donated to charities worldwide is a remarkable philanthropic effort.  We fully support the Rockefellers' commitment to giving back, and our sponsorship is VistaJet's way to facilitate and contribute to the exhibitions, auctions, and ultimately, the Rockefeller family's charitable mission. We are very proud to support their initiative as the key global partner."

The global nature of the auction and exhibitions aligns seamlessly with the VistaJet brand and its global reach. With a fleet of over 70 super-mid and long range identically designed aircraft, VistaJet guarantees availability within 24 hours to its customers, no matter where in the world they are based. The sponsorship of such a landmark collection is a way for VistaJet to support not only the arts, but David and Peggy Rockefeller's philanthropic endeavours.

Sales of The Collection of Peggy and David Rockefeller will be conducted in keeping with David Rockefeller's pledge to direct the majority of his wealth to philanthropy. All the Estate proceeds will be donated to charities, directly benefiting the philanthropic missions that have been maintained by the family for decades.

Find more info on how to enjoy The Collection of Peggy and David Rockefeller with VistaJet at VistaJet.com/TheArtOfFlying

*  Price on request - dependent on origin location, availability, cabin size, airport and slot restrictions..
**  Insurance and transportation terms and conditions apply.
*** Membership to The Cultivist upon application.

VistaJet Press Contacts:
Global and EMERI: Jennifer Farquhar | M: +44 7834 335505 | jennifer.farquhar@vistajet.com 
APAC: Amy Yang | M: +852 9080 3985 | amy.yang@vistajet.com 
USA: Michael Salamanca | M: +1 917 755 3734 | michael.salamanca@vistajet.com 
                         
About VistaJet
VistaJet is the first and only global aviation company. On its fleet of silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries worldwide. Founded in 2004 by Thomas Flohr, the company pioneered an innovative business model where customers pay only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet's signature Program service offers customers a bespoke subscription of flight hours on its fleet of mid and long-range jets, to fly them anywhere and at any time.

More VistaJet information and news at vistajet.com

Photos accompanying this announcement are available at 
http://www.globenewswire.com/NewsRoom/AttachmentNg/23769297-bca1-4a67-a687-3d839dcb602a 

http://www.globenewswire.com/NewsRoom/AttachmentNg/17a32814-f7d0-4bff-879f-7654a5747449




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VistaJet Ltd via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum